Compare REX AI Equity Premium Income ETF (AIPI) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Illumina, Inc. — how do they compare? REX AI Equity Premium Income ETF trades at $37.44, while Illumina, Inc. trades at $191.25 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | ILMN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $205.10 |
52-Week Low | $32.45 | $91.00 |
Market Cap | — | $29.12B |
Enterprise Value | — | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.45, up 0.29% with a bullish technical signal from moving averages, though oscillators indicate overbought conditions. The ETF maintains an aggressive weekly dividend distribution strategy yielding approximately 35% annually, supported by its AI-focused equity premium income structure. Recent news highlights the fund's transition to weekly distributions and questions about sustainability of high yields.
The high-yield strategy presents income opportunities but faces structural risks including potential NAV erosion if AI market momentum falters. Analyst sentiment remains cautious due to the capped upside from option-writing strategies and dependency on sustained technology sector performance for distribution sustainability.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
